Slide 1: H1 FY 2007-2008
H1 FY 2007-2008
Slide 2: Disclaimer
Disclaimer Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Slide 3: Corporate Developments
Corporate Developments
Slide 4: IN-105 human clinical data at EASD
IN-105 human clinical data at EASD Healthy Injectible, Pulmonary Nasal, Buccal Oral tablet Pancreas > portal vein > liver > periphery Periphery >portal vein >liver GI > portal vein > liver > periphery
Slide 5: IN-105 human clinical data at EASD
IN-105 human clinical data at EASD • Results of initial pharmacokinetic/pharmacodynamic studies with IN-105 were presented in a talk at the September 2007 European Association for Study of Diabetes (EASD) meeting held in Amsterdam. • In studies to date, IN-105 dosed to volunteers in tablet form was
Slide 6: IN-105 human clinical data at EASD
IN-105 human clinical data at EASD • In studies where subjects were fed a standard meal, the highest absorption of IN-105 was observed when subjects • were dosed 10-20 minutes before the meal. • Further studies are ongoing in Type 2 Diabetic subjects to determine the optimal dosing for longer term s
Slide 7: Abraxane® approved by DCGI
Abraxane® approved by DCGI • Biocon receives DCGI (Drug Controller General of India) approval to market ABRAXANE® (Nanoparticles based, albumin bound paclitaxel) in India • ABRAXANE® approved for use in breast cancer treatment • Facilitates affordable access of high-quality supportive care therapy I
Slide 8: Biocon-Abraxis licensing agreement for Abraxane®
Biocon-Abraxis licensing agreement for Abraxane® • Biocon-Abraxis BioScience sign a licensing agreement for the commercialisation of ABRAXANE in India. • Biocon will have the right to market ABRAXANE ® in Pakistan, Bangladesh, Sri Lanka, United Arab Emirates, Saudi Arabia, Kuwait and certain other P
Slide 9: Biocon-Neopharma MoU to establish Neobiocon
Biocon-Neopharma MoU to establish Neobiocon • Biocon and Abu Dhabi based pharmaceutical manufacturer Neopharma set up Neobiocon at Dubai Biotechnology and Research Park (Dubiotech), Dubai • Will provide affordable life saving drugs to the people of the UAE. • Neobiocon will develop and market life s
Slide 10: Biocon-Abraxis G-CSF licensing agreement
Biocon-Abraxis G-CSF licensing agreement • Biocon and Abraxis BioScience,Inc. sign agreement wherein Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union. • Biocon receives an upfront licensing fee • F
Slide 11: Biocon divests enzymes division for USD 115 million
Biocon divests enzymes division for USD 115 million • Biocon divested its enzymes business vertical to Novozymes A/S for USD 115 million. • The enzyme business included a broad range of industrial enzymes, food additives and process aids. • Biocon will strategically focus its activities on its bio-
Slide 12: Financial Highlights H1 2007-2008
Financial Highlights H1 2007-2008
Slide 13: Performance Highlights: H1 FY08
Performance Highlights : H1 FY 08 Revenues Rs. 553 crs PAT Rs. 107 crs • Total Income higher by 19% over H1 FY ‘07 • Operating profits higher by 31%. • PAT growth 27%. • Research services grew 43% (60% in Dollar terms)
Slide 14: Performance Highlights: H1 FY08
Performance Highlights : H1 FY 08 Revenues Rs. 553 crs PAT Rs. 107 crs • Technology and licensing revenues continued to contribute to H1 financials • R&D expenditure increased to Rs.32 crs from Rs.18 crs in previous year • Biocon completed divestment of Enzymes division to Novozymes South Asia Pvt L
Slide 15: P & L: H1 FY 08 Vs H1 FY 07
P & L : H1 FY 08 Vs H1 FY 07 (Rs. Cr) Particulars H1 FY - % on H1 FY - % on 08 Revenues 07 Revenues Revenues 553 463 EBIDTA 160 29% 122 26% PBT 109 20% 89 19% Tax 5 1% 6 1% PAT # 107 19% 84 18% # after Minority interest
Slide 16: P & L: Q2 FY 08 Vs Q2 FY 07
P & L : Q-2 FY 08 Vs Q-2 FY 07 (Rs. Cr) Particulars Q2 - 08 % on Q2 – 07 % on Revenues Revenues Revenues 280 250 EBIDTA 82 29% 67 26% PBT # 56 20% 47 19% Tax 4 1% 2 1% PAT 54 19% 45 18% # after Minority interest
Slide 17: Revenue (Segment wise)
Revenue ( Segment wise) (Rs. Cr) 553 76% 463 423 73% 338 16% 16% 7% 87 76 10% 1% 40 47 3 2 H1 FY 08 H1 FY 07 Custom Research & Tech Fees Enzymes Pharma Other Income Total
Slide 18: THANK YOU
THANK YOU